1. Interferon, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia;Burchert;Blood,2003
2. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: Results of a randomized study;Druker;Proc Am Soc Clin Onc,2002
3. Efficacy and safety of a specific inhibitor of the tyrosine kinase in chronic myeloid leukemia;Druker;N Engl J Med,2001
4. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro;Graham;Blood,2002
5. High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase;Kantarjian;Proc Am Soc Clin Onc,2002